All
Are your winter-rosy cheeks a little too rosy?
December 1st 2006An inflammatory skin disease shared by the likes of Princess Di, Bill Clinton and W.C.Fields, rosacea can start innocently with a flush on your cheeks that seems to last just a little too long. You may notice it after working out, eating spicy foods or even sipping a glass of red wine.
Making the most of pre-op evaluation
December 1st 2006Wilkes-Barre, Pa. - A careful preoperative evaluation to acquire a thorough understanding of individual risk factors is the foundation for success when performing dermatologic surgery in older patients, Christine E. Cabell, M.D., tells Dermatology Times.
FDA Goals: Agency hopes to streamline risk communication, device review
December 1st 2006National report - The Food and Drug Administration's plans for 2007 and beyond include greater attention to postmarket risks and more timely reviews of medical devices, including those used for plastic and reconstructive surgery, spokesmen say.
The ArteFill advantage: Longevity
December 1st 2006San Diego - ArteFill (Artes Medical), the latest federally approved facial filler, offers dermatologists a long lasting alternative, and, although it has come late to the party, it is the only product now approved that has a potential to remain in the face for years, experts say.
Sculptra trial shows significantly longer-lasting results
December 1st 2006Bridgewater, N.J. - Sculptra (Dermik) demonstrated significantly longer-lasting effects than CosmoPlast (Allergan Medical) in a randomized, evaluator-blinded, parallel group, multicenter study of 233 patients who sought treatment of nasolabial folds.
Physician responds to Chester Valley concerns
December 1st 2006EDITOR'S NOTE: Dr. Leon Kircik is replying to a clarification from Chester Valley Pharmaceuticals that ran in our November issue on an article in the October issue, "Vehicles often drive treatment of difficult ailments." Atopiclair is Chester Valley Pharmaceutical's product. While Dr. Kircik was not the author of the article (he was interviewed by Senior Staff Correspondent John Jesitus) he did see the article before it went to press for his approval, as is Dermatology Times' standard practice with clinical articles.